HIV
Conditions
Keywords
HIV, Viral Load, Counseling, Costs and Costs Analysis, Point-Of-Care Systems
Brief summary
The RAPID-VL study will take place in 20 HIV care health facilities in Southwestern Uganda. The study will test the hypothesis that a multi-component intervention package that targets barriers to efficient and timely HIV viral load (VL) testing will improve test ordering, speed up result turnaround times, and improve the quality of VL results counseling to patients. Phase 1 of the study will consist of a 1-year retrospective medical record review in all participating health facilities. In Phase 2 the intervention will be introduced in 10 randomly chosen health facilities, while the remaining 10 sites will continue with standard VL testing and counseling operations. The study will measure the speed and efficiency of VL testing, experiences of patients and clinicians with the intervention, and the cost of the intervention.
Detailed description
We will test the hypothesis that a multi-component intervention grounded in implementation science principles and that targets key barriers to optimal HIV viral load (VL) processing will improve viral load ordering, speed up viral load turnaround, and improve the quality of viral load counseling of results to patients within a Ugandan network of HIV care clinics. Specific objectives are as follows: Objective 1: Determine the comparative effectiveness of the RAPID-VL intervention on VL ordering and VL turnaround time: We will randomize 20 HIV clinics to the RAPID-VL multi-component intervention vs. standard of care VL procedures (n=10 clinics each, 60 patients/health facility). Objective 2: Identify facilitators and barriers to implementation, and perceived utility of the RAPID-VL intervention from both the patient and clinician perspectives. Objective 3: Determine the costs, cost-effectiveness, and incremental change costs of the RAPID-VL intervention.
Interventions
OTHERRAPID-VL study intervention
* Viral load (VL) ordering flowsheet with periodic health facility performance feedback * Rapid near-point-of-care VL testing and telephone delivery of results * Structured VL counseling package
Sponsors
Centers for Disease Control and Prevention
Infectious Diseases Research Collaboration, Uganda
Makerere University
University of California, San Francisco
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Intervention model description
Comparative effectiveness cluster-randomized trial
Eligibility
Sex/Gender
ALL
Age
2 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Phase 1, Intervention and Control Clinics: High risk subgroups of patients (n=10 each per clinic, total of 40 per clinic): registered for care, with a clinic visit within a year of the Phase 1 start date, plus the following: 1. Pregnant or breastfeeding women: Inclusion criteria: (1) pregnant or breastfeeding at any time during Phase 1, confirmed by clinic documentation 2. Children/adolescents: Inclusion criteria: (1) age 2-17 years, (2) no documentation of pregnancy in clinical record 3. Persons with most recent VL unsuppressed (i.e. detectable): Inclusion criteria: (1) any age, (2) most recent VL documented in the medical record within the last 1 year, with a value of \>1000 copies/mL on any assay, (3) no documentation of pregnancy in clinical record 4. Persons with no VL in last one year: Inclusion criteria: (1) any age, (2) last VL is dated \>1 year ago (if ever started on ART) or no VL on file (if never started ART) (3) no documentation of pregnancy in clinical record Non-high-risk patients (n=20 per clinic): Inclusion criteria (1) adult (age ≥18 years), (2) registered for care, with clinic visit within a year of the Phase 1 start date, (3) already on ART or starting ART at time of study enrollment, (4) do not meet any of the inclusion criteria of a high risk subgroup Phase 2, Intervention Clinics: We will select 60 patients in each of the 10 intervention clinics (600 patients total; different than the 60 patients in each clinic studied in Phase 1), with inclusion criteria as follows: High risk subgroups of patients (n=10 each per clinic, total of 40 per clinic): registered for care, with a clinic visit within a year of the Phase 2 start date; able to consent for study participation; plus the following: 1. Pregnant or breastfeeding women: Inclusion criteria: (1) currently pregnant or breastfeeding, confirmed by clinic standard documentation 2. Children/adolescents: Inclusion criteria: (1) age 2-17 years, (2) parent/guardian able and willing to provide affirmative consent for study participation, except in the case of mature or emancipated minors, (3) no documentation of pregnancy in the clinic record 3. Persons with most recent VL unsuppressed: Inclusion criteria: (1) any age, (2) most recent VL documented in the medical record within the last 1 year, with a value of \>1000 copies/mL on any assay, (3) no documentation of pregnancy in the clinical record 4. Persons with no VL in last 1 year: Inclusion criteria: (1) any age, (2) last VL is dated \>1 year ago (if ever started ART) or no VL on file (if never started ART , (3) no documentation of pregnancy in the clinical record Non-high-risk patients (n=20 per clinic): Inclusion criteria: (1) adult (age ≥18 years), (2) registered in the general HIV clinic, (3) already on ART or starting ART at time of study enrollment, (4) do not meet any of the inclusion criteria of a high risk subgroup Phase 2, Control Clinics: We will select 60 patients in each of the 10 control clinics (600 patients total; different than the 60 patients in each clinic studied in Phase 1), with inclusion criteria as follows High risk subgroups of patients (n=10 each per clinic, total of 40 per clinic): registered for care, with a clinic visit within a year of the Phase 1 start date; able to provide consent; plus the following: 1. Pregnant or breastfeeding women: Inclusion criteria: (1) pregnant or breastfeeding at any time during Phase 2, confirmed by clinic documentation 2. Children/adolescents: Inclusion criteria: (1) age 2-17 years, (2) parent/guardian able and willing to provide affirmative consent for study participation, except in the case of mature or emancipated minors, (3) no documentation of pregnancy in clinical record 3. Persons with most recent VL suppressed: Inclusion criteria: (1) any age, (2) most recent VL documented in the medical record within the last 1 year, with a value of \>1000 copies/mL on any assay, (3) no documentation of pregnancy in clinical record 4. Persons with no VL in last 1 year: Inclusion criteria: (1) any age, (2) last VL is dated \>1 year ago (if ever started ART) or no VL on file (if never started ART), (3) no documentation of pregnancy in clinical record Non-high-risk patients (n=20 per clinic): Inclusion criteria: (1) adult (age ≥18 years), (2) registered for care, with clinic visit within a year of the Phase 2 start date, (3) already on ART or starting ART at time of study enrollment, (4) do not meet any of the inclusion criteria of a high risk subgroup
Exclusion criteria
None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| VL turnaround time | 1 year | Mean turnaround time in days from VL ordering to delivery of results to patient |
| Successful VL ordering | 1 year | Proportion of patients who had a VL ordered when indicated by country guidelines |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients changed from 1st line to 2nd line ART | 1 year | Number of patients who switched to a 2nd line ART regimen for any reason |
| VL suppression 12 months after the start of Phase 2 of trial | 12 months after the start of Phase 2 of trial | Proportion of subjects suppressed 12 months after start of RAPID-VL participation |
| VL results in CPHL database | 12 months after the start of Phase 2 of trial | Proportion of VL results generated in study that are present in CPHL database at study end |
| CPHL integration process | 12 months after the start of Phase 2 of trial | Establishment of a process for data transfer to Uganda's Central Public Health Laboratory (CPHL) (yes/no) |
| Viral re-suppression after positive VL | 1 year | Proportion of patients with a positive (unsuppressed) VL whose next subsequent VL was suppressed |
Countries
Uganda
Outcome results
None listed